Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT03122262 - Dolutegravir + Emtricitabine + Tenofovir alafenamide vs Dolutegravir + Emtricitabine + Tenofovir Disoproxil vs Efavirenz + Emtricitabine - Tenofovir Disoproxil & Acquired Immune Deficiency Syndrome (AIDS) / HIV

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen. There was significantly more weight gain with the DTG-containing regimens, especially in combination with TAF, than with the standard-care regimen
Venter et al. 2019 N Engl J Med 381: 803-815…

References (Sources)

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Venter et al. 2019 N Engl J Med 381: 803-815

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

NCT03122262 - Dolutegravir + Emtricitabine + Tenofovir alafenamide vs Dolutegravir + Emtricitabine + Tenofovir Disoproxil vs Efavirenz + Emtricitabine - Tenofovir Disoproxil & Acquired Immune Deficiency Syndrome (AIDS) / HIV

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat

Links